Prostatype Genomics ABOSTO:PROGEN -4.23%25 Current Ratio is 0.44 as of Dec. 2025, which is 75% below its 10-year median of 1.74. GuruFocus rates OSTO:PROGEN with a GF Score™ of 25/100 and a GF Value™ of kr0.11 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, Prostatype Genomics AB ranks worse than 93.46% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Prostatype Genomics AB's current ratio for the quarter that ended in Dec. 2025 was 0.44.
Prostatype Genomics AB has a current ratio of 0.44. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Prostatype Genomics AB has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Prostatype Genomics AB's Current Ratio or its related term are showing as below:
OSTO:PROGEN'
s Current Ratio Range Over the Past 10 Years
Min: 0.44 Med: 1.74 Max: 6.29
Current: 0.44
During the past 7 years, Prostatype Genomics AB's highest Current Ratio was 6.29. The lowest was 0.44. And the median was 1.74.
OSTO:PROGEN's Current Ratio is ranked worse than 93.46% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs OSTO:PROGEN: 0.44
Prostatype Genomics AB (OSTO:PROGEN) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Prostatype Genomics AB Current Ratio Related Terms
Prostatype Genomics AB Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:PROGEN vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Prostatype Genomics AB's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Prostatype Genomics AB Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Prostatype Genomics AB's Current Ratio distribution charts can be found below:
* The bar in red indicates where Prostatype Genomics AB's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Prostatype Genomics AB (OSTO:PROGEN) has a Current Ratio of 0.44 as of Dec. 2025. This is 75% below median its historical median of 1.74. Over the past decade, Prostatype Genomics AB's Current Ratio has ranged from 0.44 to 6.29. According to the industry distribution chart, Prostatype Genomics AB ranks #200 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 93.5%.
Is Prostatype Genomics AB's Current Ratio too high?
Prostatype Genomics AB's current Current Ratio of 0.44 is 75% below median its 10-year median of 1.74. Over the past 10 years, this metric has ranged from a low of 0.44 to a high of 6.29. The Medical Diagnostics & Research industry median Current Ratio is 2.06. Prostatype Genomics AB's value of 0.44 is 78.6% below this industry median. Based on the distribution chart, Prostatype Genomics AB ranks #200 out of 214 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Prostatype Genomics AB has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Prostatype Genomics AB ranks #200 out of 214 companies for Current Ratio. This places Prostatype Genomics AB in the lower half of its industry. The industry median Current Ratio is 2.06. Prostatype Genomics AB's value of 0.44 is 78.6% below this benchmark. Historically, Prostatype Genomics AB's own Current Ratio has ranged from 0.44 to 6.29 over the past decade. While the company's 10-year median is 1.74 vs. the industry median of 2.06, Prostatype Genomics AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.06, based on 214 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Prostatype Genomics AB's current Current Ratio of 0.44 is 78.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Prostatype Genomics AB's current Current Ratio is 0.44, which is 75% below median its own 10-year median of 1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.11, compared to a current price of kr0.43 — trading 290.9% above its estimated fair value. The current Current Ratio is 0.44, which is 75% below median its 10-year median of 1.74 and 78.6% below the Medical Diagnostics & Research industry median of 2.06. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current Current Ratio is 0.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?
Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued.
The current stock price of kr0.43 is trading 290.9% above its estimated GF Value™ of kr0.11.
GuruFocus considers Prostatype Genomics AB to be Significantly Overvalued.
Key valuation signals for OSTO:PROGEN:
Current Ratio: 0.44 (75% below median its 10-year median of 1.74)
GF Value™: kr0.11 vs. price of kr0.43 (290.9% above fair value)
Industry Position: 78.6% below the Medical Diagnostics & Research median (#200 of 214)
No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score
Get the complete analysis for OSTO:PROGEN
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:PROGEN has been successfully added to your 
